Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Landscape, 2023

Gastroesophageal Reflux Disease (GERD) or acid reflux is a condition in which the content of the stomach regurgitates (backs up, or refluxes) into the esophagus. The refluxate is usually acidic and can cause inflammation and erosions.

Gastroesophageal reflux disease can cause due to frequent acid reflux or reflux of nonacidic content from the stomach, If the sphincter does not relax as it should or it weakens, stomach acid can flow back into the esophagus. This constant backwash of acid irritates the lining of the esophagus, often causing it to become inflamed.

Symptoms of gastroesophageal reflux disease includes chronic heartburn and acid regurgitation, a burning sensation in chest (heartburn), usually after eating, which might be worse at night or while lying down, upper abdominal or chest pain.

Doctors most often diagnose gastroesophageal reflux disease by asking about symptoms. The tests include ambulatory 24-hour pH probe, esophogram, upper endoscopy, esophageal manometry, esophageal pH monitoring.

The most common investigative treatment include proton pump inhibitors. Symptoms can be eased through lifestyle changes and home remedies like eating smaller and more frequent meals each day instead of a few large meals which promotes digestion and can aid in preventing heartburn, quit smoking, avoid lying down for at least two hours after a meal or after drinking acidic beverages, like soda, or other caffeinated beverages.

Report Highlights

Global Insight Service’s, Gastroesophageal Reflux Disease (GERD) - Drug Pipeline Landscape, 2023 report provides an overview of the Gastroesophageal Reflux Disease (GERD) pipeline drugs. This report covers detailed insights on Gastroesophageal Reflux Disease (GERD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gastroesophageal Reflux Disease (GERD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

List of Tables
List of Figures
1. Introduction
1.1 Gastroesophageal Reflux Disease (GERD) – Pipeline Drugs, 2023 - Coverage
2. Disease Overview – Gastroesophageal Reflux Disease (GERD)
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Gastroesophageal Reflux Disease (GERD) – Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Late-Stage Drugs - Pre-Registration
5.1.1 DWP14012
5.1.2 IN-C004
5.1.3 KFP-H008
5.2 Clinical Stage Drugs - Phase III
5.2.1 BLI5100
5.2.2 OCN-101
5.2.3 Vonoprazan
5.3 Clinical Stage Drugs - Phase II
5.3.1 Naronapride
5.3.2 X842
5.4 Clinical Stage Drugs - Phase I
5.4.1 AD-212
5.4.2 AD-213
5.4.3 AD-214
5.4.4 Anaprazole Sodium
5.4.5 Dexlansoprazole (Pediatric)
5.4.6 IN-C001
5.4.7 IN-C005
5.5 Early-Stage Drugs - Preclinical
5.5.1 Drug for GERD
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Addpharma Inc
9.2 Cinclus Pharma AG
9.3 Daewoong Pharmaceutical Co LTD
9.4 Hana Pharm Co Ltd
9.5 HK inno.N Corp
9.6 Jiangsu Carephar Pharmaceutical Co Ltd
9.7 Onconic Therapeutics Inc
9.8 Phathom Pharmaceuticals, Inc
9.9 Renexxion LLC
9.10 Sebela Pharmaceuticals
9.11 Takeda
9.12 Xuanzhu Biopharmaceutical Co Ltd
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products Under development for Gastroesophageal Reflux Disease (GERD)
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - BLI5100/Sebela Pharmaceuticals
Table 2.2 Clinical Trial Details - OCN-101/Onconic Therapeutics Inc
Table 2.3 Clinical Trial Details - Vonoprazan/Phathom Pharmaceuticals, Inc
Table 2.4 Clinical Trial Details - X842/Cinclus Pharma AG
Table 2.5 Clinical Trial Details - AD-213/Addpharma Inc
Table 2.6 Clinical Trial Details - AD-214/Addpharma Inc
Table 2.7 Clinical Trial Details - Anaprazole Sodium/Xuanzhu Biopharmaceutical Co Ltd
Table 2.8 Clinical Trial Details - Dexlansoprazole (Pediatric)/Takeda
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Gastroesophageal Reflux Disease (GERD), 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Gastroesophageal Reflux Disease (GERD), 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings